Clinical Trial Update: Safety Study of Gene Therapy for Ischemic Heart Disease in Korea [Phase 1, Phase 2]

View source ↗

Summary

This document reports safety results from a Phase 1/2 gene therapy trial (VM202) for ischemic heart disease in Korea. Results were posted on 2025-10-03.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ischemic Heart Disease

Drugs mentioned

• VM202 (hepatocyte growth factor gene therapy)

Snippet

Sponsor: Helixmith Co., Ltd. | Conditions: Ischemic Heart Disease | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-10-03